AMiPD: Astrocyte Metabolism in Parkinson’s Disease
The project at a glance
About
Growing evidence points to the alteration of astrocyte function and mitochondrial dysfunction as significant contributors to Parkinson’s disease (PD) and α-synuclein (α-syn) pathology. The Astrocyte Metabolism in Parkinson’s Disease (AMiPD) project aims to elucidate how α-syn pathology influences astrocytic metabolism and its subsequent effects on neurodegeneration in PD.
The project aims to use a multi-omics data approach to identify metabolic alterations in α-syn mutant astrocytes. The primary objective is to develop a multiscale computational model capable of simulating astrocytic metabolism, integrating spatial and morphological features to predict metabolic changes accurately. Experimental validation will include metabolomic profiling and mitochondrial characterization in astrocytes derived from iPSCs of α-syn mutation carriers, as well as post-mortem brain tissues.
This interdisciplinary approach bridges wet lab and computational biology, offering insights into PD pathogenesis and identifying potential therapeutic targets.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie Actions grant agreement 101081455.
Organisation and partners
Faculty of Science, Technology and Medicine (FSTM)
Luxembourg Centre for Systems Biomedicine (LCSB)
Institute for Advanced Studies (IAS)
European Commission